Physicians likely to have an ally in Tom Price at HHS

John Gregory | | Health Exec | Policy & Regulations

The nominee to run HHS under President-elect Donald Trump has a history of putting doctors’ interests first.

As Kaiser Health News reports, U.S. Rep. Tom Price, MD, R-Georgia, has sponsored several bills in recent years aimed at promoting the freedom and financial interests of physicians. Most of them failed to pass, such as implementing caps on malpractice suits and limiting background checks on physicians by regulators and hospitals, but as the leader of HHS, his policy priorities will have more weight.

“Instead of having a secretary for the people, you have a secretary for the medical profession,” said Case Western University law professor Max Mehlman, who specializes in medical malpractice litigation.

Price would be the first MD to lead HHS since the administration of President George H. W. Bush. While major medical associations are on board with his nomination—largely because of his medical background—individual members of those groups have harshly criticized the quick endorsement.

For more on how Price’s past proposals offer hints on his priorities at HHS, click on the link below: 

Price Poised To Protect Doctors’ Interests At HHS

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT
Kentucky AG launches criminal probe after conscious man nearly has organs harvested
FDA announces Class I recall of ventilators after 3 patient injuries
FDA clears AI tool that flags signs of heart disease in chest CT scans
Stewardship Health sale to private equity finalized for $245M
Baxter producing IV solutions ahead of schedule at Asheville-area site

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup